HK34278A - Derivatives of 17alpha-hydroxy-androst-4ene-17beta-carboxylic acids - Google Patents

Derivatives of 17alpha-hydroxy-androst-4ene-17beta-carboxylic acids

Info

Publication number
HK34278A
HK34278A HK342/78A HK34278A HK34278A HK 34278 A HK34278 A HK 34278A HK 342/78 A HK342/78 A HK 342/78A HK 34278 A HK34278 A HK 34278A HK 34278 A HK34278 A HK 34278A
Authority
HK
Hong Kong
Prior art keywords
4ene
17alpha
17beta
androst
hydroxy
Prior art date
Application number
HK342/78A
Inventor
G H Phillipps
P J May
Original Assignee
Glaxo Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Lab Ltd filed Critical Glaxo Lab Ltd
Publication of HK34278A publication Critical patent/HK34278A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Steroid Compounds (AREA)
HK342/78A 1971-01-20 1978-06-29 Derivatives of 17alpha-hydroxy-androst-4ene-17beta-carboxylic acids HK34278A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB278771A GB1384372A (en) 1971-01-20 1971-01-20 Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids

Publications (1)

Publication Number Publication Date
HK34278A true HK34278A (en) 1978-07-07

Family

ID=9745890

Family Applications (1)

Application Number Title Priority Date Filing Date
HK342/78A HK34278A (en) 1971-01-20 1978-06-29 Derivatives of 17alpha-hydroxy-androst-4ene-17beta-carboxylic acids

Country Status (17)

Country Link
JP (1) JPS5611720B1 (en)
AU (1) AU473868B2 (en)
BE (1) BE778285A (en)
CA (1) CA1003820A (en)
CH (1) CH602786A5 (en)
DE (1) DE2202691A1 (en)
DK (1) DK132894C (en)
ES (1) ES399057A1 (en)
FR (1) FR2122539B1 (en)
GB (1) GB1384372A (en)
HK (1) HK34278A (en)
IE (1) IE36000B1 (en)
IL (1) IL38589A (en)
NL (1) NL172511C (en)
NO (1) NO137321C (en)
SE (1) SE383522B (en)
ZA (1) ZA72401B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1438940A (en) * 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
DE2365102C2 (en) * 1973-12-21 1982-12-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen New pregnanic acid derivatives
DE2444618C2 (en) * 1974-09-16 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen New Pregnan-21-Acid-Derivatives
DE2319479C2 (en) * 1973-04-14 1982-10-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Pregnanic acid derivatives, processes for their production and pharmaceutical preparations containing them
GB1514476A (en) * 1974-08-30 1978-06-14 Glaxo Lab Ltd Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates
SE427276B (en) * 1975-04-03 1983-03-21 Hoffmann La Roche PROCEDURE FOR PREPARING D-HOMOSTEROIDS
CH628355A5 (en) * 1976-02-24 1982-02-26 Ciba Geigy Ag METHOD FOR PRODUCING NEW ANDROSTADIEN-17BETA-CARBONIC ACIDS AND THEIR ESTERS AND SALTS.
IT1114534B (en) * 1978-02-08 1986-01-27 Glaxo Group Ltd ANTI-INFLAMMATORY STEROID OF THE ANDROSTANE SERIES COMPOSITIONS THAT CONTAIN IT AND PROCEDURE TO PRODUCE IT
CA1138857A (en) * 1979-01-24 1983-01-04 Leo Alig D-homosteroids
SE449106B (en) * 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd STEROID WITH ANTI-INFLAMMATORY EFFECT AND COMPOSITION CONTAINING THIS
JPS59139315A (en) * 1983-01-31 1984-08-10 Taisho Pharmaceut Co Ltd Cream agent
US4607028A (en) * 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters
US5981517A (en) * 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
SI1775305T1 (en) 2000-08-05 2015-01-30 Glaxo Group Limited 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxyĆ-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothiotic acid s-fluoromethyl ester as an anti-inflammatory agent
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
SI1383786T1 (en) 2001-04-30 2009-02-28 Glaxo Group Ltd Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US7419971B2 (en) 2003-06-19 2008-09-02 Bodor Nicholas S Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application
ES2339351T3 (en) 2003-06-19 2010-05-19 Nicholas S. Bodor IMPROVEMENT OF THE ACTIVITY AND / OR DURATION OF THE ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION.
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
ATE517908T1 (en) 2005-01-10 2011-08-15 Glaxo Group Ltd ANDROSTAN-17-ALPHA-CARBONATE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC AND INFLAMMATORY CONDITIONS
US7691811B2 (en) 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US7687484B2 (en) 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
DE102010029877A1 (en) 2010-06-09 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Preparing 1,4-pregna-dienoic acid derivative from 20-hydroxysteroid derivative by Swern oxidation, comprises adding 20-hydroxysteroid derivative in mixture of e.g. secondary amine and dimethylsulfoxide, and adding chlorosulfonic acid
DE102010029875A1 (en) 2010-06-09 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Preparing 1,4-pregna-dienoic acid derivatives, comprises oxidizing 20-oxo-steroid derivatives to 20-hydroxysteroid derivatives in the presence of copper(II) salts with hydroxyalkyl, and oxidizing the 20-oxo-steroid derivatives
US8835410B2 (en) 2011-05-10 2014-09-16 Bodor Laboratories, Inc. Treatment of eyelid dermatitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636010A (en) * 1968-12-23 1972-01-18 Ciba Geigy Corp Esters of steroid-17-carboxylic acids

Also Published As

Publication number Publication date
NL7200818A (en) 1972-07-24
NO137321B (en) 1977-10-31
BE778285A (en) 1972-07-20
FR2122539A1 (en) 1972-09-01
IL38589A (en) 1976-06-30
AU3811072A (en) 1973-07-26
FR2122539B1 (en) 1975-11-28
NL172511B (en) 1983-04-18
CA1003820A (en) 1977-01-18
IL38589A0 (en) 1972-03-28
ES399057A1 (en) 1974-11-01
JPS5611720B1 (en) 1981-03-16
SE383522B (en) 1976-03-15
NO137321C (en) 1978-02-08
GB1384372A (en) 1975-02-19
IE36000B1 (en) 1976-07-21
ZA72401B (en) 1973-09-26
DK132894C (en) 1976-07-26
AU473868B2 (en) 1976-07-08
IE36000L (en) 1972-07-20
DK132894B (en) 1976-02-23
DE2202691A1 (en) 1972-08-03
CH602786A5 (en) 1978-08-15
NL172511C (en) 1983-09-16

Similar Documents

Publication Publication Date Title
HK34278A (en) Derivatives of 17alpha-hydroxy-androst-4ene-17beta-carboxylic acids
JPS56158777A (en) Manufacture of substituted-4oxo-4h-1-benzopyrane- 2-carboxylic acids
IL40521A (en) 1-heterocyclyl-3-indolealkanoic acid derivatives
GB1403002A (en) Preparation of penam derivatives
IL40833A (en) Derivatives of 1-amino-3-phenoxypropan-2-ol
AU4847172A (en) Cycloalkylaminoarylcarboxylic acid derivatives
IE36280L (en) Preparation of desoxyribonucleic acids
MY7900097A (en) Phosphorus-containing ester derivatives of hydroxytriazoles
IE37237L (en) Pyrroleacetic acid derivatives
ZA723646B (en) Derivatives of perfluorated carboxylic acids
IL41380A0 (en) Preparation of 2-alkoxy-5-alkyl-sulphonyl-benzoic acids
PH10267A (en) New derivatives of 4-chloro-5-sulfamoyl-anthranilic acid
MY7500276A (en) 2-chloroethanephosphonic acid derivatives
GB1401285A (en) Derivatives of alpha-aminocephalosporins
IL39481A (en) Derivatives of 9-oxo-13-trans-prostenoic acid
AU5969373A (en) Preparation of derivatives of 5-hydroxy-2-carboxychromone
AU473516B2 (en) Derivatives of 22-fluoro-digoxins
ZA735959B (en) 4-ethers of 3-amino-5-sulfamoylbenzoic acids
IL39343A0 (en) The preparation of 4-hydroxy-benzodioxole derivatives
ZA725797B (en) Hydroxy-ether-carboxylic acids
GB1405794A (en) Alpha-thioacetic acid derivatives
ZA725043B (en) New derivatives of dibenzodioxepine
CA876119A (en) Direct mono-esterification of arylmalonic acids
JPS5581864A (en) Manufacture of 55fluorouracil derivative
ZA724921B (en) Esters of 9a-fluoro-16-methylene-prednisolone